Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label PK Study of Mirikizumab in Pediatric Patients With Moderately to Severely Active Ulcerative Colitis

NCT04004611 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT04004611
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04004611 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label PK Study of Mirikizumab in Pediatric Patients With Moderately to Severely Active Ulcerative Colitis
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
May 18, 2020
Completion date
March 15, 2023
Enrollment
26 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis